The EMA at 20: Guido Rasi looks at how the EU regulatory landscape might change over the next decade
This article was originally published in Scrip
Executive Summary
The drug development landscape has changed markedly over the 20 years since the EMA was founded in 1995, with a pronounced shift away from the blockbuster model to a more personalized approach involving diagnostic tools, more patient involvement, and the earlier availability of promising new drugs for unmet needs. Maureen Kenny and Ian Schofield spoke to Guido Rasi, former EMA executive director and now its principal adviser on strategy, about the complexity of the EU regulatory system, why it's OK to give companies scientific advice, and what the drug evaluation landscape might look like in the next 10-20 years.
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.